The aim of this study is to evaluate the safety and effectivity of Ginkgo diterpene lactone meglumine injection tn the treatment of acute ischemic stroke

This trial is a randomized, double-blind, placebo-controlled trial, A total of approximately 80 patients (age > 40 years) with acute ischemic stroke (5\

Inclusion Criteria:

• Aged > 40 years, and gender not limited;
• Within 48 hours of stroke onset of ischemic stroke;
• The first onset, or always not obvious legacy of stroke sequela;
• A score of 5-24 points on the National Institute of Health Stroke Scale (NIHSS)；
• Understand and voluntarily signed informed consent.

Exclusion Criteria:

• Cardiogenic cerebral embolism;
• AIS caused by other definite causes (e.g., arterial dissection, vasculitis, vascular malformation, etc.) or undetermined etiology;
• Treated with thrombolysis or intravascular therapy, or with arteriovenous bridging after onset;
• Under dual antiplatelet therapy or anticoagulant therapy;
• A score of more than 2 on the modified Rankin Scale (mRS) (scores range from 0 [no symptoms] to 6 [death]) before the occurrence of AIS;
• Allergy or contraindication to GDLI or aspirin;
• Patients with active bleeding or bleeding tendency, malignancies, severe liver (the serum level of AST and/or ALT > 2 times the upper limit of normal), or renal failure (the serum level of creatinine > 1.5 times the upper limit of normal or GFR < 40 ml/min/1.73m2);
• Anticipated requirement for long-term nonstudy antiplatelet drugs or for nonsteroidal anti-inflammatory drugs affecting platelet function;
• Severe noncardiovascular coexisting condition, with a life expectancy of less than 3 months;
• Planned surgery or interventional treatment requiring cessation of the study drug;
• Pregnancy, lactation, or planning to get pregnant.